Drug news
NICE recommends Harvoni (ledipasvir + sofosbuvir) for treatment of hepatitis C genotypes 1 and 4- Gilead
The National Institute for Health and Care Excellence in draft guidelines recommends Harvoni (ledipasvir + sofosbuvir) for patients with genotype 1 and genotype 4 hepatitis C. Harvoni is a once a day, oral, drug which offers interferon and ribavirin free treatment with a potential short course of eight weeks.
Comment: Harvoni offers advantages of a reduction of the complications found with interferon such as liver cirrhosis and is likely to encourage compliance and a reduction in transmission of the disease.